[表现为病理非特异性间质性肺炎模式的间质性肺炎患者中CA19-9的临床特征]

[Clinical characterization of CA19-9 in patients with interstitial pneumonia showing pathological nonspecific interstitial pneumonia pattern].

作者信息

Totani Yoshitaka, Saito Yuji, Miyachi Hiromi, Yoneda Yukiko, Shimizu Hideyasu, Hoshino Tami, Hayashi Masamichi, Uchiyama Yasuhiro, Isogai Sumito, Matsui Kiyoshi, Hashimoto Yasushi, Umemoto Masaya, Sasaki Fumihiko, Okazawa Mitsushi, Sakakibara Hiroki

机构信息

Division of Respirology& Allergology, Department of Internal Medicine, School of Medicine, Fujita Health University.

出版信息

Nihon Kokyuki Gakkai Zasshi. 2005 Feb;43(2):77-83.

PMID:15770937

Abstract

OBJECTIVE AND METHODS

To assess the clinical significance of CA19-9 in patients with interstitial pneumonia showing pathological nonspecific interstitial pneumonia (NSIP) pattern (IP/NSIP groups), we measured the levels of serum (n = 14) and bronchoalveolar lavage fluid (BALF, n = 10) CA19-9 in IP/NSIP groups.

RESULT

The serum levels of CA19-9 did not correlate with the serum levels of LDH, of KL-6, or of SP-D or with the intensity of chest Ga-67 scintigraphy. There were no significant differences between the serum CA19-9 levels before therapy and those after therapy in improving patients. The levels of CA19-9 in fibrotic NSIP groups (serum:n = 7, 138.3 + /- 79.6 U/ml BALF: n = 5, 845.8 + /- 334.2 U/ml) were significantly higher than those in cellular NSIP groups (serum: n = 7, 12.8 +/-2.1 U/ml, BALF: n = 5, 40.8 +/- 16.2 U/ml). Immunohistochemical stains of CA19-9 showed the strong positivity in the bronchiolar epitheliums located in severe fibrotic lesions and the mucus within the lumens of microscopic honeycomb. The serum levels of CA19-9 were increased in both worsening patients.

CONCLUSION

We speculated that the serum levels of CA19-9 may reflect the progression of lung fibrosis but not the disease activity in IP-NSIP groups.

摘要

目的与方法

为评估CA19-9在表现为病理非特异性间质性肺炎（NSIP）模式的间质性肺炎患者（IP/NSIP组）中的临床意义，我们测定了IP/NSIP组血清（n = 14）和支气管肺泡灌洗液（BALF，n = 10）中CA19-9的水平。

结果

CA19-9的血清水平与乳酸脱氢酶（LDH）、KL-6、表面活性蛋白D（SP-D）的血清水平或胸部镓-67闪烁显像的强度均无相关性。病情改善患者治疗前和治疗后的血清CA19-9水平无显著差异。纤维化NSIP组（血清：n = 7，138.3±79.6 U/ml；BALF：n = 5，845.8±334.2 U/ml）的CA19-9水平显著高于细胞性NSIP组（血清：n = 7，12.8±2.1 U/ml；BALF：n = 5，40.8±16.2 U/ml）。CA19-9的免疫组化染色显示，位于严重纤维化病变处的细支气管上皮及微小蜂窝腔内的黏液呈强阳性。病情恶化的患者血清CA19-9水平均升高。